Debiopharm exercises option for AD drug

Switzerland's Debiopharm has exercised its option right by signing a licensing agreement with the Shanghai Institute of Materia Medica, China, for the development of ZT-1, a novel cholinesterase inhibitor for the treatment of Alzheimer's disease.

Under the terms of the deal, Debiopharm has obtained worldwide development and commercialization rights to ZT-1, excluding China. The agent is a huperzine A derivative which, as well as its cholinergic effects, has potentially neuroprotective properties which could reduce the progression of the disease, noted the Swiss firm.

To date, ZT-1 has undergone numerous preclinical studies, as well as seven Phase I/II clinical trials. Debiopharm is currently looking for partners to further develop the drug.